

# Inês Esteves Domingues Pires da Silva, MD FRACP PhD

---

Melanoma Institute Australia  
The Poche Centre, 40 Rocklands Rd,  
Wollstonecraft NSW 2065

Phone #: +61 406 182 575  
Email: [Ines.Silva@melanoma.org.au](mailto:Ines.Silva@melanoma.org.au)

---

## Personal Statement

---

**Inês Silva, MD FRACP PhD** is a Medical Oncologist at Melanoma Institute Australia, Blacktown and Mater Hospitals, and Senior Lecturer at The University of Sydney.

Dr Silva received her MD degree at the Universidade Nova de Lisboa (Lisbon, Portugal) and completed specialist training in Medical Oncology at Instituto Português de Oncologia (Lisbon, Portugal). She did her PhD at Bhardwaj Lab (part of Interdisciplinary Melanoma Cooperative Group and New York University [NYU] Cancer Institute, New York, United States of America) in tumour immunology, describing how the dysfunction of the protective innate immune mechanisms, including NK cells, can contribute towards melanoma progression. She did two clinical fellowships in melanoma, one at NYU Cancer Institute (2014), and more recently, at Melanoma Institute Australia (2017-2019) where she was co-investigator in phase I, II and III clinical trials (neoadjuvant, adjuvant and metastatic) in melanoma.

Dr Silva has presented her research work in several meetings (SMR, ESMO) and oral presentations at SITC, AACR, ASCO and ESMO; and she got the best poster award at ESMO 2019 and Cancer Conquer merit award in 2019, 2020 and 2021, including the Bradley Stuart Beller Endowed Merit Award for the highest ranking ASCO abstract overall (2020). She has over 50 publications, including 1st author publications in Lancet Oncology, Journal of Clinical Oncology, Cancer Cell, NEJM and JTC, amongst others, senior author in JTC publication, and co-author of publications in Cancer Cell and JCI on the field of melanoma and immuno-oncology.

Dr Silva's main research interests are (1) Biomarkers of response to immunotherapy and targeted therapy in melanoma; (2) Mechanisms of innate and adaptive resistance with immunotherapy; (3) Patterns of metastization and patterns of response to immunotherapy; (4) Mechanism of toxicity with immunotherapy.

## Medical Employment

---

Nov 2021-current	Melanoma Institute Australia The University of Sydney, Sydney, Australia <b>Medical Oncologist and Associate Professor</b>
July 2021-current	Blacktown Hospital <b>Medical Oncology Staff Specialist</b>
Feb 2020-Jun 2021	Westmead and Blacktown Hospitals The University of Sydney, Sydney, Australia <b>Medical Oncology Clinical and Research Fellow</b> Supervisors: Adnan Nagrial, MD PhD; Matteo Carlino, MD PhD
Jan 2018-Jan 2020	Melanoma Institute Australia The University of Sydney, Sydney, Australia <b>Medical Oncology Research Fellow</b> Supervisors: Georgina Long, MD PhD; Richard Scolyer MD PhD
	Melanoma Institute Australia The University of Sydney, Sydney, Australia

Sept 2016-Dec 2017	<b>Medical Oncology Clinical Fellow</b> Medical Director: Georgina Long, MD PhD
May 2016-Aug 2016	Instituto Português de Oncologia de Lisboa Francisco Gentil Nova Medical School <b>Medical Oncology Consultant</b> Medical Director: António Moreira, MD
Jul 2013-Jul 2014	Interdisciplinary Melanoma Cooperative Group (IMCG) Cancer Institute, NYU Langone Medical Center, USA <b>Clinical and Research Fellow</b> Supervisors: Anna Pavlick, MD; Iman Osman, MD
Jul 2010-Jun 2013	Programme for Advanced Medical Education, Gulbenkian Foundation, Lisboa, Portugal & Cancer Institute, NYU Langone Medical Center, NYC, USA <b>MD PhD Student</b> Supervisors: Nina Bhardwaj, MD PhD; Passos Coelho, MD PhD; Iman Osman, MD
Jan 2007-Abril 2016	Medical Oncology Department of Instituto Português de Oncologia, Lisboa, Portugal <b>Medical Oncology Resident</b> Supervisor: Isabel Sargento, MD; Oncology Department Chief: António Moreira, MD
Jan-Dec 2006	Hospitais Civis de Lisboa, Portugal <b>Intern</b>

## Medical Education

---

1999-2005	Faculdade de Ciências Médicas of Universidade Nova de Lisboa <b>Medical Degree</b> Lisbon, Portugal
-----------	---

## Certificates

---

### Investigator Site Personnel ICH GCP Training Certificate

- 4 Janeiro 2024

### Harvard Medical School-Portugal Program in Translational Research and Information

- Clinical Scholars Research Training (CSRT) certificate program I and II
- Post-graduation course
- November 2015

### ESMO Examination Certificate

- 50 Category 1 ESMO-MORA points
- September 2015

### HSPH-HMS214x: Fundamentals of Clinical Trials

- 17 February 2014

## **Certification by Educational Commission for Foreign Medical Graduates (ECFMG)**

- USMLE Step 1 – August 2012
- USMLE step 2 CK - February 2013
- USMLE step 2 CS - February 2013

## **Grants/Scholarships and Awards**

---

### **2023: NHMRC Ideas Grant (CIA)**

Sponsors: NHMRC

Project Title: Liver metastases: a niche of resistance and of therapeutic opportunities for all cancers.

### **2023: Sydney Cancer Partners Pilot Study**

Sponsors: Sydney Cancer Partners

Project Title: Identifying the immune populations driving response to immune checkpoint blockade therapies.

### **2022: Wildfire highly cited publication**

Sponsors: CINSW

Publication Title: Distinct Immune Cell Populations Define Response to Anti-PD-to 1 Monotherapy and Anti-PD-to 1/Anti-CTLA-to 4 Combined Therapy (Cancer Cell, 2019 Feb 11; 35(2) 238-to 255).

Role: co-author

### **2022: CINSW Early Career Fellowship**

Sponsors: CINSW

Project Title: Matching optimal drug therapy to overcome organ-specific resistance to standard immunotherapy in melanoma

### **2022: CINSW Project Grant**

Sponsors: CINSW

Project Title: Personalised Immunotherapy Program – Precision immunotherapies for multiple solid tumours using a biomarker driven adaptive enrichment clinical trials platform.

### **2021: Best oral presentation award (Oncology Spring Meeting)**

Project title: Clinical models predictive of response and survival in advanced melanoma patients treated with anti-PD1 monotherapy or in combination with anti-CTLA-4

### **2021-2022 WSLHD REN Internal Grant Scheme**

Sponsors: WSLHD and its Research and Education Network

Project title: Risk factors of immune-checkpoint inhibitors mediated liver, gastrointestinal, endocrine and skin toxicity (ICEMELT).

### **2021: Conquer Cancer Merit Award**

Sponsors: Conquer Cancer

Project title: Patterns and management of progression on 1st line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients.

### **2020: Bradley Stuart Beller Endowed Merit Award for the highest ranking abstract overall**

Sponsors: Conquer Cancer, supported by Friends and Family of Dr. and Mrs. Ronald Beller

Project title: Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.

### **2020: Team Science Award Focused on In-Transit Melanoma**

Sponsors: Melanoma Research Alliance

Project title: Effective therapies for patients with high risk in-transit disease.

Role: Co-investigator

**2020: AMRF Post Graduate Scholar Support Grant**

Sponsors: Australian Melanoma Research Foundation

Project Title: Liver metastases from melanoma primary

Role: Co-investigator

**2020: Pilot and Seed Award**

Sponsors: Sydney Catalyst

Project title: Improving Survival in Melanoma by Matching Optimal Drug Therapy For Individual Patients (CIA)

Role: Principal investigator

**2020: Tour de Cure**

Sponsors: Tour de Cure

Project title: Improving survival in melanoma by matching optimal drug therapy for individual patients.

Role: Co-investigator

**2019: Best Poster Award**

Sponsors: ESMO 2019

Project title: Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts).

**2019: Travel Grant**

Sponsors: Sydney Catalyst

Project title: Clinical models to predict response and survival in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+PD1).

**2019: Conquer Cancer Merit Award**

Sponsors: Conquer Cancer

Project title: Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy.

**2019: Travel Grant**

Sponsors: Melanoma Institute Australia

Project title: Liver metastases (mets) induce systemic immunosuppression and immunotherapy resistance in metastatic melanoma.

**2018: Travel Grant**

Sponsors: Melanoma Institute Australia

Project title: Melanoma liver metastases (mets) are immunosuppressive and have a distinct clinical and genetic profile.

Project title: Blood and clinical predictors of response and toxicity (tox) in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+PD1).

**2018: Travel Grant**

Sponsors: Melanoma Institute Australia

Project title: Distinct patterns of response and toxicity by sites of metastases in patients treated with ipilimumab combined with PD-1 antibodies.

**2017: Travel Grant**

Sponsors: Melanoma Institute Australia

Project title: Distinct gene expression, mutational profile and clinical outcomes of V600E and V600K/R BRAFmutant metastatic melanoma (MM).

Project title: Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1).

**2016: Grant**

Sponsors: Instituto Português de Oncologia de Lisboa Francisco Gentil

Project title: Study of the association of the imunomodulatory effect of the dual HER2 blockade and clinical response to these drugs in the context of HER2+ Advanced Breast Cancer

**2015: Best oral presentation award (Oncology Spring Meeting)**

Project title: Evaluation of clinical and immunological outcomes of the association of anti-CTLA-4 with radiotherapy and/or steroids.

**2015: Best poster presentation award (3<sup>rd</sup> Portuguese Melanoma Symposium)**

Project title: Identification of a novel pathogenic germline KDR variant in melanoma.

**2009-2013: Scholarship**

Sponsors: Gulbenkian and Champalimaud's Foundation

**2008: Scholarship for a rotation overseas**

Sponsors: Portuguese Cancer Council

**Contributions to Science**

My contribution to science is indicated by the >50 papers on which I was an author (1st author in 20 papers), with more than 2000 citations (i10-index = 30; h-index = 23). I conceived and led all projects on which I am first author and that contributed to the impact of our research program.

My clinical experience and networking allowed me to design, develop and lead important and clinical relevant projects in collaboration with international cancer centres which: (1) established ipilimumab combined with anti-PD1 as second line immunotherapy in anti-PD(L)1 resistant melanoma patients (Pires da Silva I *et al.* Lancet Oncology 2021); (2) showed that anti-CTLA-4 monotherapy or in combination with anti-PD-1 after failing anti-PD1+anti-LAG3 has poor efficacy, with objective response rate of 11% and median progression-free survival of 2.6 months in advanced melanoma patients (Menzies AM\*, Pires da Silva I\*, *et al* (\*contributed equally). NEJM 2022); (3) confirmed that treatment with immune checkpoint inhibitors is safe in cancer patients infected with COVID-19 (Rogiers A\*, Pires da Silva I\*, *et al* (\*contributed equally). JTC 2021).

This privileged position of clinician and researcher allowed me to bring clinically relevant questions into the lab, and vice versa, to bring findings from the lab to clinical discussion. In collaboration with other researchers and clinicians, I have led many translational research projects which constitute a relevant contribution to our research program: (1) identifying biomarkers of response to immunotherapy (Pires da Silva I *et al.*, JCO 2022; Newell F\*, Pires da Silva I\* *et al* (\*contributed equally). Cancer Cell 2022; Pires da Silva I *et al*, CCR 2019); (2) unveiling mechanisms of resistance to immunotherapies and identifying novel therapeutic targets (Pires da Silva I *et al.* CIR 2014). I have also shown that liver metastases are resistant to immunotherapy, and their presence is associated with poor outcomes (Pires da Silva I *et al*, Cancer 2019). This project led to other research projects that I'm leading in order to unveil mechanisms of resistance specific to the liver (Oral presentation AACR 2019) and to define patterns of melanoma metastases and their survival (Best Poster Award ESMO 2019); (3) establishing biomarkers and management of immune-related toxicities (Pires da Silva I *et al*, PCMR 2019).

**Research Experience****2020-current, Blacktown Hospital, Sydney, Australia**

- I am principal investigator of 6 phase I-III trials.
- I am sub-investigator of more than 30 phase I, II and III clinical trials.

**2020-current, Melanoma Institute Australia, Sydney, Australia**

- Conception & design of 2 investigator-led trials in non-melanoma skin cancers
- I am principal investigator of 3 phase II and III trials in non-melanoma skin cancers
- I am sub-investigator of more than 35 phase II and III clinical trials including pharma (2/3 of total number of trials) and investigator-led trials (1/3 of total number of trials), having recruited more than three hundred patients to these trials.

**2016-2019, Melanoma Institute Australia, Sydney, Australia**

Supervisor: Georgina Long, MD PhD

- Conception & design of several translational research projects in the following areas:
  1. Biomarkers of response to immunotherapy and targeted therapy in melanoma.
  2. Mechanisms of innate and adaptive resistance.
  3. Patterns of metastatization and patterns of response to immunotherapy.
  4. Mechanism of toxicity with immunotherapy.
- I am sub-investigator of more than 35 phase II and III clinical trials including pharma (2/3 of total number of trials) and investigator-led trials (1/3 of total number of trials), having recruited more than three hundred patients to these trials.

#### **2014-2016, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal**

Supervisor: António Moreira, MD

- Conception & design of two translational research projects:
  1. Study of the association of the immunomodulatory effect of the dual HER2 blockade and clinical response to these drugs in the context of HER2+ Advanced Breast Cancer
  2. Study of the quantification of BARF-1 RNA and DNA as predictive marker of response to treatment in undifferentiated nasopharyngeal cancer patients (Vebinaso Study)

#### **2010-2014, New York University Medical Center, New York, USA**

Supervisor: Nina Bhardwaj, MD PhD; Iman Osman, MD

- Title PhD thesis: "Immunotherapy in Melanoma: the role of NK cells"  
During four years I have developed translational work in the field of immune-oncology, mainly in studying the NK cell exhaustion and immune checkpoint blockade in the context of melanoma
- Design, protocol writing, development and implementation, and recruitment to two clinical trials (NCT01079741 and NCT00821652)

#### **Publications**

1. McNamee N, Harvey C, Gray L, Khoo T, Lingam L, Zhang B, Nindra U, Yip PY, Pal A, Clay T, Arulananda S, Itchins M, Pavlakis N, Kao S, Bowyer S, Chin V, Warburton L, Pires da Silva I, John T, Solomon B, Alexander M, Nagrial A. Brief Report: Real-world toxicity and survival of combination immunotherapy in pleural mesothelioma – RIOMeso. *JTO (in press)*.
2. Conway JW, Braden J, Lo SN, Scolyer RA, Carlino MS, Menzies AM, Long GV, Pires da Silva I. VEGF Inhibitors Improve Survival Outcomes in Patients with Liver Metastases across Cancer Types-A Meta-Analysis. *Cancers (Basel)*. 2023 Oct 16;15(20):5012. doi: 10.3390/cancers15205012. **PMID: 37894379**.
3. Adegoke NA, Gide TN, Mao Y, Quek C, Patrick E, Carlino MS, Lo SN, Menzies AM, Pires da Silva I, Vergara IA, Long G, Scolyer RA, Wilmott JS. Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies. *J Immunother Cancer*. 2023 Oct;11(10):e007144. doi: 10.1136/jitc-2023-007144. **PMID: 37865395**.
4. Mao Y, Gide TN, Adegoke NA, Quek C, Maher N, Potter A, Patrick E, Saw RPM, Thompson JF, Spillane AJ, Shannon KF, Carlino MS, Lo SN, Menzies AM, Pires da Silva I, Long GV, Scolyer RA, Wilmott JA. *J Transl Med*. 2023 Apr 13;21(1):257. doi: 10.1186/s12967-023-04092-9. **PMID: 37055772**.
5. Gide TN, Paver EC, Yaseen Z, Maher N, Adegoke N, Menzies AM, Pires da Silva I, Wilmott J, Long GV, Scolyer RA. *Oncoimmunology*. 2023 Oct 4;12(1):2261248. doi: 10.1080/2162402X.2023.2261248. eCollection 2023. **PMID: 37808404**.
6. Shteinman ER, Vergara IA, Rawson RV, Lo SN, Scolyer RA, Pires da Silva I, Wilmott JS, Long GV, Menzies AM. Molecular and clinical correlates of HER3 expression in melanoma. *Pathology* 2023. *(in press)*.
7. Pham JP, Joshua AM, Pires da Silva I, Dummer R, Goldinger SM. Chemotherapy in cutaneous melanoma; is there still a role? *Current Oncology Reports*. 2023 Mar 29. doi: 10.1007/s11912-023-01385-6. **PMID: 36988735**.

8. Weppler AM, Da Meda L, Pires da Silva I, Xu W, Grignani G, Menzies AM, Carlino MS, Long GV, Lo SN, Nordman I, Steer CB, Lyle M, Trojaniello C, Ascierto PA, Lebbe C, Sandhu S. Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. *Eur J Cancer*. 2023 Jan 30;183:109-118. doi: 10.1016/j.ejca.2023.01.016. **PMID: 36842413**.
9. Lee H, Ferguson AL, Quek C, Vergara IA, Pires da Silva I, Allen R, Gide TN, Conway JW, Koufariotis LT, Hayward NK, Waddell N, Carlino MS, Menzies AM, Saw RPM, Shklovskaya E, Rizos H, Lo S, Scolyer RA, Long GV, Palendira U, Wilmott JS. Intratumoral CD16+ macrophages are associated with clinical outcomes of patients with metastatic melanoma treated with combination anti-PD-1 and anti-CTLA-4 therapy. *Clin Cancer Res*. 2023 Feb 15;CCR-22-2657. doi: 10.1158/1078-0432.CCR-22-2657. **PMID: 36790412**.
10. Boys E, Gao B, Hui R, Pires da Silva I, Hau E, Gee H, Nagrial A. Use of durvalumab in stage III non-small-cell lung cancer based on eligibility for the PACIFIC study. *Thorac Cancer*. 2023. doi: 10.1111/1759-7714.14780. Epub 2023 Jan 10. **PMID: 36627112**.
11. Wong SK, Blum SM, Sun X, Pires da Silva I, Zubiri L, Ye F, Bai K, Zhang K, Ugurel S, Zimmer L, Livingstone E, Schadendorf D, Serra-Bellver P, Munoz-Couselo E, Ortiz C, Lostes J, Huertas RM, Arance A, Pickering L, Long GV, Carlino MS, Buchbinder EI, Vazquez-Cortes L, Jara-Casas D, Marquez-Rodas I, Gonzalez-Espinosa I, Balko JM, Menzies AM, Sullivan RJ, Johnson DB. Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma. *Eur J Cancer*. 2023 Mar;181:188-197. doi: 10.1016/j.ejca. **PMID: 36680880**.
12. Brown LJ, Pires da Silva I, Moujaber T, Gao B, Hui R, Gurney H, Carlino M, Nagrial A. Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres. *Cancer Med*. 2022 Nov 20. doi: 10.1002/cam4.5468. **PMID: 36404632**.
13. Conway JW, Braden J, Wilmott JS, Scolyer RA, Long GV, Pires da Silva I. The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. *Front Immunol*. 2022 Nov 17. doi: 10.3389/fimmu.2022. **PMID: 36466910**.
14. Nahar KJ, Marsh-Wakefield F, Rawson RV, Gide TN, Ferguson AL, Allen RO, Quek C, Pires da Silva I, Tattersall S, Kiely CJ, Sandanayake, Carlino MS, McCaughan G, Wilmott JS, Scolyer RA, Long GV, Menzies AM, Palendira U. Distinct pre-treatment innate immune landscape and post-treatment T cell responses underlie immunotherapy-induced colitis. *JCI Insight* 2022, Nov 8; 7(21): e157839. **PMID: 36173679**.
15. Shteinman ER, Wilmott JS, Pires Da Silva I, Long GV, Scolyer RA, Vergara IA. Causes, consequences and clinical significance of aneuploidy across melanoma subtypes. *Frontiers in Oncology* 2022; 12: 988691. **PMID: 36276131**.
16. Serra-Bellver P, Versluis JM, Oberoi HK, Zhou C, Slattery TD, Khan Y, Patrinely JR, Pires da Silva I, Martinez-Vila C, Cook N, Graham DM, Carlino MS, Menzies AM, Arance AM, Douglas DB, Long GV, Pickering L, Larkin JMG; Blank CU, Lorigan P. Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study. *European Journal of Cancer* 2022 Nov;176:121-132. doi: 10.1016/j.ejca.2022.09.004. **PMID: 36215945**.
17. Simpson RC, Shanahan ER, Batten M, Reijers ILM, Read M, Pires da Silva I, Versluis JM, Ribeiro R, Angelatos AS, Tan J, Adhikari C, Menzies AM, Saw RPM, Gonzalez M, Shannon KF, Spillane AJ, Velickovic R, Lazar AJ, Damania AV, Mishra AK, Chelvanambi M, Banerjee A, Ajami NJ, Wargo JA, Macia L, Holmes AJ, Wilmott JS, Blank CU, Scolyer RA, Long GV. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. *Nature Medicine* 2022 Sep 22. doi: 10.1038/s41591-022-01965-2. Epub ahead of print. **PMID: 36138151**.
18. Conway JW, Rawson RV, Lo S, Ahmed T, Vergara IA, Gide TN, Attrill GH, Carlino MS, Saw RPM, Thompson JF, Spillane AJ, Shannon KF, Shivalingam B, Menzies AM, Wilmott JS, Long GV, Scolyer RA, Pires da Silva I. Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites. *Journal for*

19. Attrill GH, Lee H, Tasker AT, Adegoke NA, Ferguson AL, Pires da Silva I, Saw RPM, Thompson JF, Palendira U, Long GV, Ferguson PM, Scolyer RA, Wilmott JS. Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome. *Front Immunol.* 2022;13:979993. Published 2022 Aug 8. doi:10.3389/fimmu.2022.979993. **PMID: 36003398.**

20. Pires da Silva I, Zakria D, Ahmed T, Trojaniello C, Dimitriou F, Allayous C, Gerard CL, Zimmer L, Lo SN, Michielin O, Lebbe C, Mangana J, Ascierto PA, Johnson DB, Carlino MS, Menzies AM, Long GV. Efficacy and Safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. *Journal for ImmunoTherapy of Cancer* 2022;10:e004610. doi:10.1136/jitc-2022-004610. **PMID: 35798536.**

21. Attrill GH, Owen CN, Ahmed T, Vergara IA, Colebatch AJ, Conway JW, Nahar KJ, Thompson JF, Pires da Silva I, Carlino MS, Menzies AM, Lo S, Palendira U, Scolyer RA, Long GV, Wilmott JS. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. *J Immunother Cancer.* 2022 Jun;10(6):e004771. doi: 10.1136/jitc-2022-004771. **PMID: 35688560.**

22. Li AT, Miin Yip J, Choksi H, London K, Potter AJ, Lo SN, Saw RPM, Shannon KF, Pires da Silva I, Varey AHR, Menzies AM, Long GV, Shivalingam B, Scolyer RA, Thompson JF, Ch'ng S. Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread. *Melanoma Res.* 2022 May 13. doi: 10.1097/CMR.0000000000000827. Epub ahead of print. **PMID: 35579680.**

23. Menzies AM\*, Pires da Silva I\*, Trojaniello C, Vieu E, Amaria RN, Zimmer L, Lo SN, Burton EM, Tawbi HA, Schadendorf D, Grob JJ, Ascierto PA, Long GV (\*contributed equally to this work). CTLA-4 Blockade Resistance after Relatlimab and Nivolumab. *N Engl J Med.* 2022 Apr 28;386(17):1668-1669. doi: 10.1056/NEJMc2119768. **PMID: 35476655.**

24. Pires da Silva I\*, Ahmed T\*, McQuade JL, Nebhan CA, Park JJ, Versluis JM, Serra-Bellver P, Khan Y, Slattery T, Oberoi HK, Ugurel S, Haydu LE, Herbst R, Utikal J, Pföhler C, Terheyden P, Weichenthal M, Gutzmer R, Mohr P, Rai R, Smith JL, Scolyer RA, Arance AM, Pickering L, Larkin J, Lorigan P, Blank CU, Schadendorf D, Davies MA, Carlino MS, Johnson DB, Long GV, Lo SN, Menzies AM (\*contributed equally to this work). Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. *J Clin Oncol.* 2022 Apr 1;40(10):1068-1080. doi: 10.1200/JCO.21.01701. Epub 2022 Feb 10. **PMID: 35143285.**

25. Newell F\*, Pires da Silva I\*, Johansson PA\*, Menzies AM\*, Wilmott JS\*, Addala V, Carlino MS, Rizos H, Nones K, Edwards JJ, Lakis V, Kazakoff SH, Mukhopadhyay P, Ferguson PM, Leonard C, Koufariotis LT, Wood S, Blank CU, Thompson JF, Spillane AJ, Saw RPM, Shannon KF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA, Waddell N, Long GV (\*contributed equally to this work). Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. *Cancer Cell.* 2022 Jan 10;40(1):88-102.e7. doi: 10.1016/j.ccr.2021.11.012. Epub 2021 Dec 23. **PMID: 34951955.**

26. Scolyer RA, Atkinson V, Gyorki DE, Lambie D, O'Toole S, Saw RPM, Amanuel B, Angel CM, Button-Sloan AE, Carlino MS, Ch'ng S, Colebatch AJ, Daneshvar D, Pires da Silva I, Dawson T, Ferguson PM, Foster-Smith E, Fox SB, Gill AJ, Gupta R, Henderson MA, Hong AM, Howle JR, Jackett LA, James C, Lee CS, Lochhead A, Loh D, McArthur GA, McLean CA, Menzies AM, Nieweg OE, O'Brien BH, Pennington TE, Potter AJ, Prakash S, Rawson RV, Read RL, Rtshiladze MA, Shannon KF, Smithers BM, Spillane AJ, Stretch JR, Thompson JF, Tucker P, Varey AHR, Vilain RE, Wood BA, Long GV. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. *Pathology.* 2022 Feb;54(1):6-19. doi: 10.1016/j.pathol.2021.11.002. Epub 2021 Dec 20. **PMID: 34937664.**

27. Pires da Silva I, Ahmed T, Reijers ILM, Warner AB, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Zimmer L, Trojaniello C, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA, Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Menzies AM, Long GV. Ipilimumab versus ipilimumab plus anti-

PD-1 for metastatic melanoma - Authors' reply. *Lancet Oncol.* 2021 Aug;22(8):e343-e344. doi: 10.1016/S1470-2045(21)00419-8. **PMID: 34339647.**

28. Gide TN\*, Pires da Silva I\*, Quek C, Ferguson PM, Batten M, Shang P, Ahmed T, Menzies AM, Carlino MS, Saw RPM, Thompson JF, Scolyer RA, Long GV, Wilmott JS. Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. *Cancers (Basel)*. 2021 Jun 25;13(13):3186. doi: 10.3390/cancers13133186. **PMID: 34202352.**

29. Haas L, Elewaut A, Gerard CL, Umkehrer C, Leiendecker L, Pedersen M, Krecioch I, Hoffmann D, Novatchkova M, Kuttke M, Neumann T, Pires da Silva I, Witthock H, Cuendet MA, Carotta S, Harrington KJ, Zuber J, Scolyer RA, Long GV, Wilmott JS, Michielin O, Vanharanta S, Wiesner T, Obenauf AC. Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. *Nat Cancer*. 2021 Jul;2(7):693-708. doi: 10.1038/s43018-021-00221-9. Epub 2021 Jul 15. **PMID: 35121945.**

30. Ch'ng S, Uyulmaz S, Carlino MS, Pennington TE, Shannon KF, Rtshiladze M, Stretch JR, Nieweg OE, Varey AHR, Hsiao E, Kapoor R, Pires da Silva I, Lo SN, Spillane AJ, Scolyer RA, Long GV, Hong AM, Saw RPM, Thompson JF, Menzies AM. Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. *Eur J Cancer*. 2021 Aug;153:8-15. doi: 10.1016/j.ejca.2021.04.037. Epub 2021 Jun 12. **PMID: 34126335.**

31. Hepner A, Atkinson VG, Larkin J, Burrell RA, Carlino MS, Johnson DB, Zimmer L, Tsai KK, Klein O, Lo SN, Haydon A, Bhave P, Lyle M, Pallan L, Pires da Silva I, Gerard C, Michielin O, Long GV, Menzies AM. Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy. *Eur J Cancer*. 2021 Aug;153:213-222. doi: 10.1016/j.ejca.2021.04.021. Epub 2021 Jun 29. **PMID: 34214936.**

32. Lee H, Pires da Silva I, Palendira U, Scolyer RA, Long GV, Wilmott JS. Targeting NK Cells to Enhance Melanoma Response to Immunotherapies. *Cancers (Basel)*. 2021 Mar 17;13(6):1363. doi: 10.3390/cancers13061363. **PMID: 33802954.**

33. Kelly GM, Al-Ejeh F, McCuaig R, Casciello F, Ahmad Kamal N, Ferguson B, Pritchard AL, Ali S, Pires da Silva I, Wilmott JS, Long GV, Scolyer RA, Rao S, Hayward NK, Gannon F, Lee JS. G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma. *Clin Cancer Res*. 2021 May 1;27(9):2624-2635. doi: 10.1158/1078-0432.CCR-20-3463. Epub 2021 Feb 15. **PMID: 33589432.**

34. Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Nguyen K, Zimmer L, Trojaniello C, Stout D, Lyle M, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA, Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Blank CU, Menzies AM, Long GV. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. *Lancet Oncol*. 2021 Jun;22(6):836-847. doi: 10.1016/S1470-2045(21)00097-8. Epub 2021 May 11. **PMID: 33989557.**

35. Rogiers A\*, Pires da Silva I\*, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, Zubiri L, Manos M, Bowling P, Elkrief A, Papneja N, Vitale MG, Rose AAN, Borgers JSW, Roy S, Mangana J, Pimentel Muniz T, Cooksley T, Lupu J, Vaisman A, Saibil SD, Butler MO, Menzies AM, Carlino MS, Erdmann M, Berking C, Zimmer L, Schadendorf D, Pala L, Queirolo P, Posch C, Hauschild A, Dummer R, Haanen J, Blank CU, Robert C, Sullivan RJ, Ascierto PA, Miller WH Jr, Stephen Hodi F, Suijkerbuijk KPM, Reynolds KL, Rahma OE, Lorigan PC, Carvajal RD, Lo S, Mandala M, Long GV (\*contributed equally to this work). Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. *J Immunother Cancer*. 2021 Jan;9(1):e001931. doi: 10.1136/jitc-2020-001931. **PMID: 33468556.**

36. Hoefsmit EP, Rozeman EA, Van TM, Dimitriadis P, Krijgsman O, Conway JW, Pires da Silva I, van der Wal JE, Ketelaars SLC, Bresser K, Broeks A, Kerkhoven RM, Reeves JW, Warren S, Kvistborg P, Scolyer RA, Kapiteijn EW, Peper DS, Long GV, Schumacher TNM, Blank CU. Comprehensive analysis of cutaneous and uveal melanoma liver metastases. *J Immunother Cancer*. 2020 Dec;8(2):e001501. doi: 10.1136/jitc-2020-001501. **PMID: 33262254.**

37. Edwards J, Ferguson PM, Lo SN, Pires da Silva I, Colebatch AJ, Lee H, Saw RPM, Thompson JF, Menzies AM, Long GV, Newell F, Pearson JV, Waddell N, Hayward NK, Johansson PA, Mann GJ, Scolyer RA, Palendira U, Wilmott JS. Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas. *Cancer Immunol Res*. 2020 Nov;8(11):1346-1353. doi: 10.1158/2326-6066.CIR-19-0835. Epub 2020 Sep 11. **PMID: 32917657**.

38. Gide TN, Pires da Silva I, Quek C, Ahmed T, Menzies AM, Carlino MS, Saw RPM, Thompson JF, Batten M, Long GV, Scolyer RA, Wilmott JS. Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. *Oncoimmunology*. 2019 Oct 16;9(1):1659093. doi: 10.1080/2162402X.2019.1659093. **PMID: 32002281**.

39. Castelo-Branco L\*, Pires da Silva I\*, Canhão H, Awada A. Promising Immuno-Oncology Treatments Beyond the 2018 Nobel Prize (\*contributed equally to this work). *Acta Med Port*. 2019 Apr 30;32(4):251-257. doi: 10.20344/amp.12040. Epub 2019 Apr 30. **PMID: 31067417**.

40. Pires da Silva I, Lo S, Quek C, Gonzalez M, Carlino MS, Long GV, Menzies AM. Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. *Cancer*. 2020 Jan 1;126(1):86-97. doi: 10.1002/cncr.32522. Epub 2019 Oct 4. **PMID: 31584722**.

41. Pires da Silva I, Glitz IC, Haydu LE, Johnpulle R, Banks PD, Grass GD, Goldinger SMA, Smith JL, Everett AS, Koelblinger P, Roberts-Thomson R, Millward M, Atkinson VG, Gumiński A, Kapoor R, Conry RM, Carlino MS, Wang W, Shackleton MJ, Eroglu Z, Lo S, Hong AM, Long GV, Johnson DB, Menzies AM. Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. *Pigment Cell Melanoma Res*. 2019 Jul;32(4):553-563. doi: 10.1111/pcmr.12775. Epub 2019 Mar 3. **PMID: 30767428**.

42. Edwards J, Tasker A, Pires da Silva I, Quek C, Batten M, Ferguson A, Allen R, Allanson B, Saw RPM, Thompson JF, Menzies AM, Palendira U, Wilmott JS, Long GV, Scolyer RA. Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials. *Clin Cancer Res*. 2019 Jun 1;25(11):3247-3258. doi: 10.1158/1078-0432.CCR-18-4011. Epub 2019 Feb 18. **PMID: 30777877**.

43. Quek C, Rawson RV, Ferguson PM, Shang P, Pires da Silva I, Saw RPM, Shannon K, Thompson JF, Hayward NK, Long GV, Mann GJ, Scolyer RA, Wilmott JS. Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. *Oncotarget*. 2019 Jan 29;10(9):930-941. doi: 10.18632/oncotarget.26584. **PMID: 30847022**.

44. Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, Yan Y, Lo S, Carlino MS, Gumiński A, Saw RPM, Pang A, McGuire HM, Palendira U, Thompson JF, Rizos H, Pires da Silva I, Batten M, Scolyer RA, Long GV, Wilmott JS. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. *Cancer Cell*. 2019 Feb 11;35(2):238-255.e6. doi: 10.1016/j.ccr.2019.01.003. **PMID: 30753825**.

45. Pires da Silva I, Wang KYX, Wilmott JS, Holst J, Carlino MS, Park JJ, Quek C, Wongchenko M, Yan Y, Mann G, Johnson DB, McQuade JL, Rai R, Kefford RF, Rizos H, Scolyer RA, Yang JYH, Long GV, Menzies AM. Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma. *Clin Cancer Res*. 2019 Feb 15;25(4):1272-1279. doi: 10.1158/1078-0432.CCR-18-1680. Epub 2019 Jan 10. **PMID: 30630828**.

46. Wang KYX, Menzies AM, Pires da Silva I, Wilmott JS, Yan Y, Wongchenko M, Kefford RF, Scolyer RA, Long GV, Tarr G, Mueller S, Yang JYH. bcGST-an interactive bias-correction method to identify over-represented gene-sets in boutique arrays. *Bioinformatics*. 2019 Apr 15;35(8):1350-1357. doi: 10.1093/bioinformatics/bty783. **PMID: 30215668**.

47. Lee H, Quek C, Pires da Silva I, Tasker A, Batten M, Rizos H, Lim SY, Nur Gide T, Shang P, Attrill GH, Madore J, Edwards J, Carlino MS, Gumiński A, Saw RPM, Thompson JF, Ferguson PM, Palendira U,

Menzies AM, Long GV, Scolyer RA, Wilmott JS. Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. *Oncoimmunology*. 2018 Oct 31;8(2):e1537581. doi: 10.1080/2162402X.2018.1537581. **PMID: 30713793**.

48. Pires da Silva I, Batten M, Long GV. Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas. *Br J Cancer*. 2018 Sep;119(6):661-662. doi: 10.1038/s41416-018-0218-3. Epub 2018 Aug 21. **PMID: 30131552**.

49. Costa DA, Costa TP, Netto EC, Joaquim N, Ventura I, Pratas AC, Winckler P, Pires da Silva I, Pinho AC, Sargent IG, Guerreiro FG, Moreira AR. New perspectives on the conservative management of osteoradionecrosis of the mandible: A literature review. *Head Neck*. 2016 Nov;38(11):1708-1716. doi: 10.1002/hed.24495. Epub 2016 May 30. **PMID: 27240248**.

50. Pires da Silva I, Long GV. Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice. *Curr Opin Oncol*. 2017 Nov;29(6):484-492. doi: 10.1097/CCO.0000000000000405. **PMID: 28914644**.

51. Pires da Silva I, Salhi A, Giles KM, Vogelsang M, Han SW, Ismaili N, Lui KP, Robinson EM, Wilson MA, Shapiro RL, Pavlick A, Zhong J, Kirchhoff T, Osman I. Identification of a Novel Pathogenic Germline KDR Variant in Melanoma. *Clin Cancer Res*. 2016 May 15;22(10):2377-85. doi: 10.1158/1078-0432.CCR-15-1811. Epub 2015 Dec 2. **PMID: 26631613**.

52. Rendleman J, Vogelsang M, Bapodra A, Adaniel C, Pires da Silva I, Moogk D, Martinez CN, Fleming N, Shields J, Shapiro R, Berman R, Pavlick A, Polsky D, Shao Y, Osman I, Krosgaard M, Kirchhoff T. Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma. *J Med Genet*. 2015 Apr;52(4):231-9. doi: 10.1136/jmedgenet-2014-102832. Epub 2015 Jan 20. **PMID: 25604082**.

53. Salhi A, Farhadian JA, Giles KM, Vega-Saenz de Miera E, Pires da Silva I, Bourque C, Yeh K, Chhangawala S, Wang J, Ye F, Zhang DY, Hernando-Monge E, Houvrás Y, Osman I. RSK1 activation promotes invasion in nodular melanoma. *Am J Pathol*. 2015 Mar;185(3):704-16. doi: 10.1016/j.ajpath.2014.11.021. Epub 2015 Jan 8. **PMID: 25579842**.

54. Pires da Silva I, Gallois A, Jimenez-Baranda S, Khan S, Anderson AC, Kuchroo VK, Osman I, Bhardwaj N. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. *Cancer Immunol Res*. 2014 May;2(5):410-22. doi: 10.1158/2326-6066.CIR-13-0171. Epub 2014 Feb 11. **PMID: 24795354**.

55. Moogk D, Pires da Silva I, Ma MW, Friedman EB, de Miera EV, Darvishian F, Scanlon P, Perez-Garcia A, Pavlick AC, Bhardwaj N, Christos PJ, Osman I, Krosgaard M. Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy. *J Transl Med*. 2014 Dec 10;12:342. doi: 10.1186/s12967-014-0342-7. **PMID: 25491880**.

56. Gumaste PV, Fleming NH, Pires da Silva I, Shapiro RL, Berman RS, Zhong J, Osman I, Stein JA. Analysis of recurrence patterns in acral versus nonacral melanoma: should histologic subtype influence treatment guidelines? *J Natl Compr Canc Netw*. 2014 Dec;12(12):1706-12. doi: 10.6004/jnccn.2014.0172. **PMID: 25505211**.

57. Fleming NH, Zhong J, Pires da Silva I, Vega-Saenz de Miera E, Brady B, Han SW, Hanniford D, Wang J, Shapiro RL, Hernando E, Osman I. Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients. *Cancer*. 2015 Jan 1;121(1):51-9. doi: 10.1002/cncr.28981. Epub 2014 Aug 25. **PMID: 25155861**.

58. Scanlon P, Tian J, Zhong J, Pires da Silva I, Shapiro R, Pavlick A, Berman R, Osman I, Darvishian F. Enhanced immunohistochemical detection of neural infiltration in primary melanoma: is there a clinical value? *Hum Pathol*. 2014 Aug;45(8):1656-63. doi: 10.1016/j.humpath.2014.04.003. Epub 2014 Apr 18. **PMID: 24890944**.

59. Gallois A, Pires da Silva I, Osman I, Bhardwaj N. Reversal of natural killer cell exhaustion by TIM-3 blockade. *Oncoimmunology*. 2015 Jan 7;3(12):e946365. doi: 10.4161/21624011.2014.946365. **PMID: 25964857**.

60. Jiménez-Baranda S, Pires da Silva I, Bhardwaj N. Plasmacytoid dendritic cells lead the charge against tumors. *J Clin Invest.* 2012 Feb;122(2):481-4. doi: 10.1172/JCI61345. Epub 2012 Jan 17. **PMID: 22251700.**

61. Pires da Silva I, Tomé V, Oliveira J. Benign metastasising leiomyoma: a progressive disease despite chemical and surgical castration. *BMJ Case Rep.* 2012 Mar 27;2012:bcr0120125505. doi: 10.1136/bcr.01.2012.5505. **PMID: 22605795.**

62. Pires da Silva I, Tome V, Oliveira J. Adenoid cystic carcinoma of the breast with cerebral metastisation: a clinical novelty. *BMJ Case Rep.* 2011 Oct 4;2011:bcr0820114692. doi: 10.1136/bcr.08.2011.4692. **PMID: 22679170.**

63. Pires da Silva I, Noronha C, Panarra A, Riso N, Riscado MV. Wegener's granulomatosis: skin deep. *Acta Reumatol Port.* 2011 Jan-Mar;36(1):81-2. **PMID: 21483288.**

64. Pires da Silva I, Noronha C, Panarra A, Riso N, Riscado MV. No pulse: a medical conundrum. *Acta Reumatol Port.* 2010 Jul-Sep;35(3):393-5. **PMID: 20975648.**

65. Vanda J, Pires da Silva I, Sousa M, Noronha C, Riscado M. Feocromocitoma Associado à Neurofibromatose de Von Recklinghausen Tipo 1: um Caso Clínico Raro. *Revista da Sociedade Portuguesa de Medicina Interna.*

## Selected Presentations

---

### Oral Presentations

- **Patterns of response and progression with immune-checkpoint inhibitor combinations in advanced Non-small cell lung cancer (NSCLC)**
  - Brown LJ, Ahn J, Nagrial A, Gee H, Hau E, Pires da Silva, I.
  - Australian Lung Cancer Conference; Gold Coast, 15<sup>th</sup> – 17<sup>th</sup> February 2023
- **The role of adjuvant and neoadjuvant therapies for cutaneous Squamous Cell Carcinoma**
  - Pires da Silva I.
  - Invited speaker – Australasian Melanoma Conference; Brisbane, 24<sup>th</sup> - 25<sup>th</sup> March 2023
- **Mecanismos de resistência e novas oportunidades**
  - Pires da Silva I.
  - Invited speaker – 19th Portuguese Oncology National Congress; Porto, 16<sup>th</sup> - 18<sup>th</sup> November 2022
- **Updates in Melanoma & non melanoma skin cancers**
  - Pires da Silva I.
  - Invited speaker – Melanoma Institute Australia Educational Session; Hobart, 3<sup>rd</sup> November 2022.
- **Investigational Immunotherapy: highlights**
  - Pires da Silva I.
  - Invited speaker – European Society of Medical Oncology; Paris, 9<sup>th</sup> - 13<sup>th</sup> September 2022.
- **Basic Science**
  - Simpson RC, Shanahan ER, Batten M, Pires da Silva I, Reijers ILM, Versluis JM, Menzies AM, Saw RPM, Gonzalez M, Shannon KF, Spillane AJ, Blank CU, Scolyer RA, Long GV.
  - European Society of Medical Oncology; Paris, 9-13<sup>th</sup> September 2022.
- **Clinical Research impact**
  - Pires da Silva I.
  - Invited speaker – School of Medical Sciences Research Retreat; Sydney, 15<sup>th</sup> June 2022.

- ***Clinical and molecular biomarkers of response to immunotherapy in Melanoma***
  - Pires da Silva I.
  - Invited speaker – ONJCRI seminar; Virtual, 10<sup>th</sup> May 2022.
- ***The evolution of adjuvant and neoadjuvant therapy***
  - Pires da Silva I.
  - Invited speaker – 2022 New Zealand Melanoma Summit; Auckland, 13<sup>th</sup> February 2022.
- ***Immune related toxicities and management***
  - Pires da Silva I.
  - Invited speaker – ESMO Virtual Preceptorship; 22<sup>nd</sup> – 23<sup>rd</sup> November 2021.
- ***Management of advanced cutaneous SCC and BCC***
  - Pires da Silva I.
  - Invited speaker – Australasian Melanoma Conference; Sydney, 19<sup>th</sup> - 20<sup>th</sup> November 2021.
- ***Breaking news in Skin cancer Immunotherapy***
  - Pires da Silva I.
  - Invited speaker – III Immuno-Oncology Iberic Course; Virtual, 11<sup>th</sup> November 2021.
- ***Challenges in the Era of Immunotherapy***
  - Pires da Silva I.
  - Invited speaker – 2021 Sydney Cancer Conference; Virtual, 9th - 10th of September 2021
- ***Current management of complex skin cancer***
  - Pires da Silva I.
  - Invited speaker – The Joint Scientific Meeting of the Australian & NZ Head & Neck Cancer Society & NZ Association of Plastic Surgeons; Queenstown, 5<sup>th</sup> - 7<sup>th</sup> August 2021.
- ***Advanced melanoma: What surgeons should know***
  - Pires da Silva I.
  - Invited speaker – The Joint Scientific Meeting of the Australian & NZ Head & Neck Cancer Society & NZ Association of Plastic Surgeons; Queenstown, 5<sup>th</sup> – 7<sup>th</sup> August 2021.
- ***Early melanoma: Surgical and Medical management in the modern era***
  - Pires da Silva I.
  - Invited speaker – The Joint Scientific Meeting of the Australian & NZ Head & Neck Cancer Society & NZ Association of Plastic Surgeons; Queenstown, 5<sup>th</sup> - 7<sup>th</sup> August 2021.
- ***Immune-based therapy in Oncology: Lessons from the treatment of Melanoma***
  - Pires da Silva I.
  - Invited speaker – 2021 Cancer Immunology Ideas Forum; Sydney, 21<sup>st</sup> of May 2021.
- ***Safety/Tolerability and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab in Patients With Advanced Platinum-Resistant Ovarian Cancer (PROC)***
  - Goh JC, Coward J, Gao B, Pires da Silva I., Voskoboinik M, Day D, Body AL, Gan HK, Chen C, Xiang X, Fei C, Yang L, Millward M
  - AACR Virtual Meeting 2021; 24<sup>th</sup> June – 29th April 2020.
- ***The biology and systemic treatment of BCC and cutaneous SCC***
  - Pires da Silva I.
  - Invited speaker – Melanoma Masterclass COSA 2020.
- ***Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI)***

- Rogiers A, Tondini C, Grimes JM, Trager MH, Nahm S, Zubiri L, Papneja N, Elkrief A, Borgers J, Rose A, Mangana J, Erdmann M, Pires da Silva I, Posch C, Hauschild A, Zimmer L, Queirolo P, Robert C, Suijkerbuijk K, Ascierto PA, Lorigan P, Carvajal R, Rahma OE, Mandala M, Long GV.
- AACR Virtual Meeting: COVID-19 and Cancer 2020; 20<sup>th</sup> – 22<sup>nd</sup> Jul 2020.
- ***Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy***
  - Pires da Silva I, Ahmed T, Lo S, Reijers I, Weppler A, Betof A, Patrinely JR, Serra-bellver P, Lebbe C, Mangana J, Nguyen K, Zimmer L, Ascierto P, Haydon A, Lyle M, Klein O, Gerard C, Blank C, Menzies AM, Long GV.
  - ASCO virtual annual meeting 2020; 29<sup>th</sup> - 31<sup>st</sup> May 2020.
- ***Low intestinal microbial diversity is associated with severe immune-related adverse events and lack of response to neoadjuvant combination antiPD1, anti-CTLA4 immunotherapy***
  - Batten M, Shanahan ER, Pires da Silva I, Adhikari C, Conway J, Tasker A, Menzies AM, Wilmott JS, Saw RP, Spillane AJ, Shannon KF, Blank CU, Holmes AJ, Scolyer RA, Long GV.
  - AACR virtual annual meeting 2020; 24<sup>th</sup> – 29<sup>th</sup> April 2020.
- ***Immune checkpoint inhibitors***
  - Pires da Silva I.
  - Invited speaker – *Short Course in Oncology Therapeutic Management*; Lisbon, 26<sup>th</sup> of September 2019.
- ***CAR T cells***
  - Pires da Silva I.
  - Invited speaker – *Short Course in Oncology Therapeutic Management*; Lisbon, 26<sup>th</sup> of September 2019.
- ***The influence of the host in the response to immunotherapy: age, sex and microbiome.***
  - Pires da Silva I.
  - Invited speaker – Shaping Tomorrow: Redefining Cancer Immunotherapy; Lisbon, 11<sup>th</sup> of May 2019.
- ***Predicting response to immunotherapy: The exceptional responder – what can we learn?***
  - Pires da Silva I.
  - Invited speaker – Melanoma Biomarker Symposium; Melbourne, 18<sup>th</sup> of September 2019.
- ***Burning questions in the biology of advanced melanoma and immunotherapy.***
  - Pires da Silva I.
  - Invited speaker - MIA Research Retreat 2019; Sydney, 23<sup>rd</sup> of August 2019.
- ***Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy.***
  - Pires da Silva I.
  - ASCO annual meeting 2019; Chicago, 31<sup>st</sup> May - 4<sup>th</sup> of June 2019.
- ***Liver Metastases (mets) induce systemic immunosuppression and immunotherapy resistance in metastatic melanoma***
  - Pires da Silva I, Tasker A, Quek C, Rawson R, Lim SY, Wang K, Conway J, Velickovic R, Ahmed T, Lo S, Yang J, Rizos H, Wilmott JS, Scolyer RA, Menzies AM, Long GV.
  - AACR annual meeting 2019; Atlanta, 29<sup>th</sup> Mar – 3<sup>rd</sup> of April 2019.
- ***State of play: What do clinicians say now and why?***
  - Pires da Silva I.
  - Invited speaker - Biomarkers of Clinical Outcome in Melanoma 2018; Sydney, 23<sup>rd</sup> of August 2018.
- ***Metastatic Melanoma: Do liver metastases let the other down?***
  - Pires da Silva I.
  - Invited speaker - MIA Research Retreat 2018; Sydney, 10<sup>th</sup> of August 2018.

- **Immunotherapies for hematologic malignancies**
  - Pires da Silva I.
  - ASH review, 17-18<sup>th</sup> of February 2017.
- **Translational Research Workshop**
  - Pires da Silva I.
  - ASH review, 17-18<sup>th</sup> of February 2017.
- **Immunotherapy: rationale and clinical indications**
  - Pires da Silva I.
  - Encontros da Primavera (Portuguese Oncology Annual meeting), 7-9<sup>th</sup> of April 2016.
- **New perspectives in immunotherapy in the context of melanoma**
  - Pires da Silva I.
  - Portuguese Society for Immunology annual meeting, 3<sup>rd</sup> of June 2016.
- **Basic of Immuno-Oncology**
  - Pires da Silva I.
  - 1<sup>st</sup> Portuguese Lung Immuno-Oncology meeting, 26<sup>th</sup> of January 2016.
- **Immunotherapy: from bench to clinic**
  - Pires da Silva I.
  - 3<sup>rd</sup> Portuguese Melanoma Symposium, 31<sup>st</sup> of October 2015.
- **Evaluation of clinical and immunological outcomes of the association of anti-CTLA-4 with radiotherapy and/or steroids.**
  - Pires da Silva I.
  - Encontros da Primavera (Portuguese Oncology Annual meeting), 23-25<sup>th</sup> of April 2015.
- **Biomarkers in cancer immunotherapy**
  - Pires da Silva I.
  - Encontros da Primavera (Portuguese Oncology Annual meeting) – Immunotherapy Workshop, 23-25<sup>th</sup> of April 2015.
- **RSK1 activation promotes invasion in nodular melanoma**
  - Salhi A, Farhadian JA, Giles KM, Vega-Saenz de Miera E, Pires da Silva I., Bourque C, yeh K, Chhangawala S, Wang J, Ye F, Zhang DY, Hernando E, Houvrás Y, Osman I.
  - Melanoma Bridge Meeting 2014; Nápoles, 3-6<sup>th</sup> of December 2014.
- **Melanoma progression is associated with NK cell exhaustion**
  - Silva IP, Gallois A, Jimenez-Baranda S, Anderson AC, Kuchroo V, Osman I, Bhardwaj N.
  - SITC 29<sup>th</sup> annual meeting 2014; National Harbor, 7-9<sup>th</sup> of November 2014.
- **Identification of active somatic mutations in “triple negative” melanoma patients and clinically relevant germline variants**
  - Pires da Silva I., Salhi A, Giles K, Lui K, Ismaili N, Pavlick A, Shapiro R, Osman I.
  - Melanoma Research Program Retreat – NYU; New York, 11<sup>th</sup> of June 2014.
- **Driving the Immune System to Fight Cancer**
  - Pires da Silva I.
  - Invited speaker – Leaping Forward, Lisbon International Clinical Congress; Lisbon, 12-19<sup>th</sup> of February 2014.

#### Poster Presentations (selected)

- **The hypoxic microenvironment at different sites of melanoma metastasis**

- Conway JW, Lo SN, Vergara IA, Gide TN, Braden J, Carlino MS, Saw RPM, Thompson JF, Spillane AJ, Shannon KF, Shivalingam B, Alexander M. Menzies AM, Wilmott JS, Long GV, Scolyer RA, Pires da Silva I.
  - Poster Session – 19<sup>th</sup> SMR Annual Meeting (2022)
- ***Spatial analysis characterises cellular immunotypes of in-transit melanoma associated with response to checkpoint inhibitor immunotherapy***
  - Bai X, Quek C, Ines Silva I, Long GV, Scolyer RA, James S. Wilmott JS.
  - Poster Session – 19<sup>th</sup> SMR Annual Meeting (2022)
- ***Time-dependent prediction of development of melanoma brain metastases (MBM) from the start of BRAF/MEK inhibitors (BRAF/MEKi) or anti-PD-1(PD1)-based immunotherapy (IO)***
  - Pires da Silva I, Vergara I, Li I, Lo S, Carlino MS, Menzies AM, Scolyer RA, Long GV
  - Poster Session – 19<sup>th</sup> SMR Annual Meeting (2022), Abstract #051
- ***NeoTrio - Optimal neoadjuvant (NAT) sequencing of Anti-PD-1 and BRAF targeted therapy (TT) in BRAF mutant stage III melanoma: Results of histopathological analysis***
  - Braden J, Potter AJ, Paver E, Rowson R, Menzies AM, Carlino MS, Au-Yeung G, Saw RPM, Spillane AJ, Kerwin KF, Pennington TE, Gyorki DE, Howle J, Daneshvar D, Willmott JS, Lo SE, Pires da Silva I, Scolyer RA, Long GV.
  - Poster Session – 47th ESMO Annual Meeting (2022), Abstract #798P
- ***Patterns of response/progression and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma***
  - Mo J, Zaremba A, Inderjeeth A-J, El Zenaty P, Li A, Wicky A, Della Marta N, Gaudy Marqueste C, Bohne A-S, Festino L, Chen C, Lo S, Guminski A, Michielin O, Xu W, Lebbe C, Sandhu S, Zimmer L, Carlino M, Pires da Silva I.
  - Poster Session – 47th ESMO Annual Meeting (2022), Abstract #824P
- ***838P: Patterns of response/progressive disease and management following progressive disease with anti-PD-1 therapy in patients with advanced cutaneous Squamous Cell Carcinoma***
  - Mo J, Bohne A-S, Gaudy Marqueste C, Della Marta N, Festino L, Chen C, Lo S, Park J, Ascierto P, Ladwa R, Xu W, Gorb J-J, Hauschild A, Menzies A, Long GV, Carlino M, Pires da Silva I.
  - Poster Session – 47th ESMO Annual Meeting (2022), Abstract #838P
- ***VEGF inhibitors (VEGFi) activity in liver metastases (mets) regardless of primary cancer type: Meta-analysis and systematic review.***
  - Pires da Silva I, Lo Serigne, Conway J, Scolyer R, Carlino M, Menzies AM, Long GV.
  - Poster Session – 58th ASCO Annual Meeting (2022), Abstract #3024
- ***A biomarker guided Bayesian response-adaptive phase II trial for metastatic melanoma: The Personalized Immunotherapy Platform (PIP)-Trial design.***
  - Lo SN, Gide TN, Gonzalez M, Pires da Silva I, Menzies AA, Carlino MA, Scolyer RA, Heritier S, Wilmott JS, Long GV.
  - Poster Session – 58th ASCO Annual Meeting (2022), Abstract #TPS9599
- ***Patterns and management of progression on 1st line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients.***
  - Pires da Silva I, Versluis J, Ahmed T, Johnson D, Soon J, Allayous C, Gerard C, Mangana J, Klein O, Zimmer L, Robert C, Vitale MG, Yeoh HL, Michielin O, Lebbe C, Sandhu S, Blank CS, Carlino MS, Menzies AM, Long GV.
  - Poster Session – 57th ASCO Annual Meeting (2021), Abstract #9533
- ***Spatial distribution and immune cell infiltration at different sites of melanoma metastases (mets).***
  - Conway JW, Rawson RV, Wilmott JS, Long GC, Scolyer RA, Pires da Silva I.
  - AACR virtual annual meeting 2021; 9<sup>th</sup> – 14<sup>th</sup> April 2021.
- ***International experience of ipilimumab and nivolumab in patients with advanced melanoma.***

- Serra-Bellver P, Versluis JM, Oberoi HK, Slattery TD, Khan Y, Patrinelly JR, Pires da Silva I, Martínez-Vila C, Cook N, Graham DM, Zhou C, Gupta A, Arance Fernande AM, Johnson DB, Long GV, Pickering L, Larkin J, Blank CU, Lorigan P.
- Poster Session – 45<sup>th</sup> ESMO Annual Meeting (2020), Abstract #1106.
- **Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts).**
  - Pires da Silva I, Lo S, Carlino MS, Scolyer RA, Menzies AM, Long GV.
  - Poster Session – 45th ESMO Annual Meeting (2020), Abstract #4278.
- **Clinical models to predict response and survival in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+PD1).**
  - Pires da Silva I, Ahmed T, Lo S, Rai R, Smith JL, Park JJ, Nebhan C, Scolyer RA, Carlino MS, McQuade JL, Johnson DB, Long GV, Menzies AM.
  - Poster Session – 55<sup>th</sup> ASCO Annual Meeting, Abstract #9542; Chicago, 31<sup>st</sup> of May – 4<sup>th</sup> June 2019.
- **Melanoma liver metastases (mets) are immunosuppressive and have a distinct clinical and genetic profile.**
  - Pires da Silva I, Tasker A, Quek C, Lim E, Wang K, Ahmed T, Lo S, Yang J, Rizos H, Wilmott J, Scolyer RA, Menzies AM, Long GV.
  - Poster Session – 15<sup>th</sup> SMR Annual Meeting; Manchester, 24-27<sup>th</sup> of October 2018.
- **Blood and clinical predictors of response and toxicity (tox) in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+PD1).**
  - Pires da Silva I, Ahmed T, Rai R, Park J, Jennifer L. McQuade J, Johnson DB, Gumiński A, Carlino MS, Lo S, Scolyer R, Long V, Menzies AM.
  - Poster Session – 15th SMR Annual Meeting; Manchester, 24-27th of October 2018.
- **Transcriptomic and immunophenotypic profiles of melanoma tissue from patients (pts) treated with anti-PD-1 +/- ipilimumab to define mechanisms of response and resistance.**
  - Gide TN, Quek C, Menzies AM, Madore, J, Velickovic R, Wongchenko M, Yan Y, Carlino MS, Gumiński AD, Saw R, Pires da Silva I, Pandira U, Thompson JF, Scolyer RA, Long GV, Wilmott JS.
  - Poster Discussion Session – 54<sup>th</sup> ASCO Annual Meeting, Abstract #9553; Chicago, 1-5<sup>th</sup> of June 2018.
- **Distinct patterns of response and toxicity by sites of metastases in patients treated with ipilimumab combined with PD-1 antibodies**
  - Pires da Silva I, Lo S, Gonzalez M, Gumiński A, Long GV, Menzies A.
  - Poster Session – 54<sup>th</sup> ASCO Annual Meeting, Abstract #9553; Chicago, 1-5<sup>th</sup> of June 2018.
- **Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1).**
  - Pires da Silva I, Johnpulle R, Banks P, Grass D, Smith J, Everett A, Goldinger S, Roberts-Thomson R, Millward M, Glitzka I, Haydu L, Atkinson V, Wang T, Eroglu Z, Conry R, Shackleton M, Hong A, Long G, Jonhson D, Menzies A.
  - Poster Discussion Session – 53<sup>rd</sup> ASCO Annual Meeting, Abstract #9513; Chicago, 26-30<sup>th</sup> of May 2017.
- **Distinct gene expression, mutational profile and clinical outcomes of V600E and V600K/R BRAF-mutant metastatic melanoma (MM).**
  - Pires da Silva I, Wang K, Wilmott JS, Holst J, Carlino MS, Park J, Quek C, Wongchenko M, Yan Y, Mann G, Johnson D, McQuade J, Rai R, Kefford RF, Rizos H, Scolyer RA, Yang J, Long GV, Menzies AM.
  - Poster Session – 53<sup>rd</sup> ASCO Annual Meeting, Abstract #9541; Chicago, 26-30<sup>th</sup> of May 2017.
- **The role of neck dissection after Concomitant Chemoradiation (CCR) with Cisplatin (Cp) After Neoadjuvant (NA) Chemotherapy (CT) with Docetaxel, Cp and 5- Fluorouracil (TPF) for Patients (pts) with Locoregionally Advanced (LA) Squamous Cell Carcinomas of the Head and Neck (SCCHN)**

- Pires da Silva I, Mouta J, Winckler P, Costa D, Netto E, Alexandre T, Sargent I, Ferreira M, Moreira A.
- Poster Session – 18<sup>th</sup> ECCO / 40<sup>th</sup> ESMO European Cancer Congress, Abstract # 2 818; Viena, 25-29<sup>th</sup> of September 2015.
- ***NK cell phenotype and soluble MICA are potential prognostic markers in melanoma***
  - Pires da Silva I, Gallois A, Lui K, Salhi A, Bhardwaj N, Osman I.
  - Poster Session – 18<sup>th</sup> ECCO / 40<sup>th</sup> ESMO European Cancer Congress, Abstract #3355; Viena, 25-29<sup>th</sup> September 2015.
- ***The effect of ipilimumab on natural killer cells identifies the subset of advanced melanoma patients with clinical response.***
  - Pires da Silva I, Gallois A, Lui K, Shapiro R, Pavlick AC, Bhardwaj N, Osman I.
  - General Poster Session – 51<sup>st</sup> ASCO Annual Meeting, Abstract #9065; Chicago, 29<sup>th</sup> May to 2<sup>nd</sup> June 2015.
- ***Immunologic profile of melanoma brain metastases (MBM) in patients (pts) with prolonged survival.***
  - Lui K, Pires da Silva I, Weiss SA, Han SW, Darvishian F, Pavlick AC, Golfinos J, Moogk D, Krosgaard M, Iman Osman.
  - General Poster Session – 51<sup>st</sup> ASCO Annual Meeting, Abstract #9065; Chicago, 29<sup>th</sup> May to 2<sup>nd</sup> of June 2015.
- ***Clinical biomarkers of response to treatment with anti-CTLA-4 in advanced melanoma patients***
  - Pires da Silva I, Lui K, Salhi A, Robinson E, Osman I.
  - 2º Congresso Luso-Brasileiro, TC 23; Lisbon, 14-16<sup>th</sup> of Maio 2015.
- ***Association of natural killer (NK) cell exhaustion with melanoma progression.***
  - Pires da Silva I, Gallois A, Lui K, Shapiro R, Berman R, Pavlick A, Zhong J, Bhardwaj N, Osman I.
  - General Poster Session - 50<sup>th</sup> ASCO Annual Meeting, Abstract #9099; Chicago, 30<sup>th</sup> of Maio to 3<sup>rd</sup> of June 2014.
- ***Integration of melanoma genotyping in clinical care.***
  - Pires da Silva I, Salhi A, Lui K, Ismaili N, Wu C, Vega-Saenz de Miera E, Shapiro R, Berman R, Pavlick AC, Zhong J, Heguy A, Osman I.
  - General Poster Session – 50<sup>th</sup> ASCO Annual Meeting, Abstract #9095; Chicago, 30<sup>th</sup> May to 3<sup>rd</sup> June 2014.
- ***Clinical Outcome and CD4<sup>+</sup> Differentiation in Anti-CTLA-4/radiation and Anti-CTLA-4/steroid Therapy.***
  - Bapodra A, Pires da Silva I, Lui K, Pavlick A, Zhong J, Osman I, Krosgaard M.
  - Poster Highlights Session - 50<sup>th</sup> ASCO Annual Meeting, Abstract #3019; Chicago, 30<sup>th</sup> of May to 3<sup>rd</sup> of June 2014.
- ***Clinical utility of serum miRNAs for the prediction and early detection of recurrence in melanoma patients.***
  - Fleming N, Pires da Silva I, Vega-Saenz de Miera E, Brady B, Han S, Hanniford D, Wang J, Shapiro RL, Hernando-Monge E, Zhong J, Osman I.
  - General Poster Session - 50<sup>th</sup> ASCO Annual Meeting, Abstract #9046; Chicago, 30<sup>th</sup> of May to 3<sup>rd</sup> of June 2014.
- ***Matrix metalloproteinase-23 as a new immunotherapeutic checkpoint target in melanoma.***
  - Moogk D, Ma M, Pires da Silva I, Friedman E, Vega-Saenz de Miera E, Darvishian F, Perez-Garcia A, Scanlon P, Pavlick AC, Bhardwaj N, Christos PJ, Osman I, Krosgaard M.
  - Poster Highlights Session - 50<sup>th</sup> ASCO Annual Meeting, Abstract #3030; Chicago, 30<sup>th</sup> of May to 3<sup>rd</sup> of June 2014.
- ***Dissecting the effect of age on immune response in melanoma patients.***
  - Fleming N, Lui K, Shapiro R, Berman R, Pavlick A, Zhong J, Krosgaard, Pires da Silva I, Osman I.

- General Poster Session - 50<sup>th</sup> ASCO Annual Meeting, Abstract #9058; Chicago, 30<sup>th</sup> of May to 3<sup>rd</sup> of June 2014.
- ***Analysis of recurrence patterns in acral versus non-acral melanoma: Should histologic subtype influence treatment guidelines?***
  - Gumaste P, Fleming N, Pires da Silva I, Shapiro R, Berman R, Zhong J, Osman I, Stein JA.
  - General Poster Session - 50<sup>th</sup> ASCO Annual Meeting, Abstract #9052; Chicago, 30<sup>th</sup> of May to 3<sup>rd</sup> of June 2014.
- ***Characterization of NK cell exhaustion in melanoma at different stages.***
  - Pires da Silva I, Gallois A, Osman I, Bhardwaj N.
  - General Poster Session – 104<sup>th</sup> AACR Annual Meeting, Abstract #4862; Washington, 6-10<sup>th</sup> of Abril 2013.
- ***Tim-3 expression and function in natural killer cells from advanced melanoma patients.***
  - Pires da Silva I, Jimenez-Baranda S, Gallois A, Kuchroo V, Osman I, Bhardwaj N.
  - General Poster Session - 48<sup>th</sup> ASCO Annual Meeting, Abstract #8571; Chicago, 1-5<sup>th</sup> of June 2012.

## Mentorship

---

- Date: Mar 2022 – current  
Place: The University of Sydney  
Co-Supervisor to PhD student Lauren Brown. Title of PhD “Site-specific response patterns to immunotherapy in patients with advanced lung cancer and overcoming organ-specific resistance mechanisms”
- Date: Feb 2022 – Nov 2022  
Place: The University of Sydney  
Co-Supervisor to Honour student Ella McCutcheon. Title of thesis “Identifying and matching novel drug combinations to the correct patients in melanoma”
- Date: Feb 2022 – Nov 2022  
Place: The University of Sydney  
Co-Supervisor to Honour student Alexander Chi Wang Siu. Title of thesis “Biomarkers of response and resistance associated with lenvatinib plus anti-PD-1 combination treatment in advanced melanoma”
- Date: Jul 2021 – current  
Place: The University of Sydney  
Co-Supervisor to PhD student Jorja Braden. Title of PhD “Translational studies on the Neo-Trio trial”
- Date: Jul 2019 – current  
Place: The University of Sydney  
Co-Supervisor to PhD student Jordan Conway. Title of PhD “Liver metastases from melanoma primary”
- Date: Jul 2018 – current  
Place: Nova Medical School  
Co-Supervisor to PhD student Ana Sofia Batalha. Title of PhD “The effect of dual HER2 blockade on anti-tumour immune cells in advanced breast cancer”
- Date: Jun 2014 – Jul 2016  
Place: Instituto Português de Oncologia de Lisboa Francisco Gentil & Nova Medical School  
Medical student teaching, clinical skills, communication skills, procedures, theory tutorials.
- Date: Jun 2012 – Aug 2012  
Place: New York University

Supervisor to two Undergraduate Research Fellows as part of the NYU program.

## Conference and Symposia Organisation

- Member of the Melanoma Institute Australia Faculty
- Member of the Melanoma Institute Australia Research Committee
- Member of the Portuguese Cancer Council Research Committee
- Member of the Australasian Melanoma Conference 2023 as part of the melanoma subcommittee.
- Member of the ESMO Congress 2023 Scientific Committee as part of the melanoma and Other skin tumours track.
- Member of the ESMO Congress 2022 Scientific Committee as part of the investigational immunotherapy track.
- Member of the scientific committee for the ASN multiomics meeting 2022 (Brisbane)
- 2021-2025, ESMO Faculty for Melanoma and Other skin tumours.
- Co-chair for the Melanoma and Skin Cancer Special Interest Group in 2019-2020.

## Editor and Reviewer Commitments

- Regular reviewer for peer-reviewed scientific journals: British Medical Journal, Annals of Oncology, Journal of Clinical Oncology, Journal for Immunotherapy of cancer, Cancer Immunology Research, Cancer, European Journal of Cancer, Frontiers in Immunology, Molecular Cancer, Therapeutic Advanced Oncology, Pathology, Pigment Cell & Melanoma Research, amongst others.
- Guest editor:
  - *Life journal* special issue on Metastatic Melanoma Research
  - *Cancers* special issue on Melanoma
- Review grants:
  - Dutch Cancer Society grant applications (international, 2023)
  - Sir Charles Gairdner and Osborne Park Health Care Group Grant Funding Program (national, 2023/2024)
  - Snow Medical Research Foundation (national, 2022).
  - Sydney Catalyst travel grant review panel member (national, 2020).

## Memberships

- American Society of Clinical Oncology (ASCO)
- European Society for Medical Oncology (ESMO)
- Sydney Vital
- Sydney Catalyst
- Portuguese Medical Association
- Portuguese Society of Oncology
- Portuguese Melanoma Intergroup
- Portuguese Association for Palliative Care)
- Portuguese Society of Immunology

## Volunteer Work

- As teacher of math at a portuguese NGO (Leigos para o Desenvolvimento) for portuguese-speaking african students.

- In slum neighbourhoods of Rio de Janeiro, Brasil, in particular Favela da Tijuca, Favela do Morro dos Macacos and Mangue Seco of Ilha do Governador.
- Humanitarian Mission through AMI in Cape Verde (Ilha do Fogo), for 1,5 months, mainly Public Health, Infirmary and Emergency Activities.
- In Shechen Clinic (Boudha, Kathmandu, Nepal), attending terminally-ill patients and getting to know the Tibetan Alternative Medicine